trending Market Intelligence /marketintelligence/en/news-insights/trending/t-ptqn9qulo1nheo756zng2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Therapix Biosciences director resigns

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Therapix Biosciences director resigns

Mark Groussman has resigned as a director of Therapix Biosciences Ltd.

Groussman's resignation was not related to any disagreement with the board on any matter relating to the operations, policies or practices, according to Therapix.

Tel Aviv, Israel-based Therapix Biosciences is a specialty clinical-stage pharmaceutical company that develops drugs based on cannabinoid molecules.